Phase I Study of OriC902 in Treatment of Advanced HCC

This is an early-phase (Phase I) study testing the safety and dosing of a new drug called OriC902 in people with advanced liver cancer (hepatocellular carcinoma, or HCC) whose cancer expresses a specific protein called GPC3 and who have not responded to standard treatments. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with HCC and your tumor tests positive for the GPC3 protein - Your cancer is at an advanced stage (BCLC B or C) and is not suitable for local treatment, or it has come back after local treatment - You have already tried and failed standard treatment options **You may NOT be eligible if...** - You do not have GPC3-positive liver cancer - You have not yet tried standard treatments - You are pregnant or breastfeeding - You have serious organ dysfunction or other conditions that make the study unsafe for you Talk to your doctor to see if this trial is right for you.